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Abstract
Background: In this study, we evaluated the prevalence of primary resistance of Brazilian H. pylori
isolates to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone. In addition,
the vacA, iceA, cagA and cagE genotypes of strains isolated from Brazilian patients were determined
and associated with clinical data in an effort to correlate these four virulence markers and antibiotic
resistance.
Methods: H. pylori was cultured in 155 H. pylori-positive patients and MICs for metronidazole,
clarithromycin, amoxicillin, tetracycline, and furazolidone were determined by the agar dilution
method. Genomic DNA was extracted, and allelic variants of vacA, iceA, cagA and cagE were
identified by the polymerase chain reaction.
Results: There was a strong association between the vacA s1/cagA -positive genotype and peptic
ulcer disease (OR = 5.42, 95% CI 2.6–11.3, p = 0.0006). Additionally, infection by more virulent
strains may protect against GERD, since logistic regression showed a negative association between
the more virulent strain, vacA s1/cagA-positive genotype and GERD (OR = 0.26, 95% CI 0.08–0.8,
p = 0.03). Resistance to metronidazole was detected in 75 patients (55%), to amoxicillin in 54
individuals (38%), to clarithromycin in 23 patients (16%), to tetracycline in 13 patients (9%), and to
furazolidone in 19 individuals (13%). No significant correlation between pathogenicity and
resistance or susceptibility was detected when MIC values for each antibiotic were compared with
different vacA, iceA, cagA and cagE genotypes.
Conclusion: The analysis of virulence genes revealed a specific association between H. pylori
strains and clinical outcome, furthermore, no significant association was detected among
pathogenicity and resistance or susceptibility.
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Background
Helicobacter pylori is a gastric pathogen that chronically
infects more than half of the world's population, with a
prevalence ranging from 25% in developed countries to
more than 90% in developing areas [1]. Infection with H.
pylori is associated with chronic superficial gastritis, peptic
ulceration and gastric cancer. The reason for such a clini-
cally diverse outcome of infection remains uncertain, but
may include host and environmental factors as well as dif-
ferences in the prevalence or expression of bacterial viru-
lence factors [1].
The cagA gene (cytotoxin-associated gene) is considered to
be a marker for the presence of a pathogenicity island (cag
PAI), and individuals infected with cagA-positive H. pylori
strains have a higher risk of developing peptic ulcers and
gastric cancer [2–4]. Several studies have reported that
some strains may contain a partially-deleted cag PAI [5].
Thus, the presence of the cagA gene does not guarantee
that critical genes within the cag PAI are intact [6], how-
ever the cagE gene appears to be a better marker of intact
cag PAI than the cagA gene [6,7].
The vacA gene encodes a vacuolating toxin excreted by H.
pylori, which has been associated with epithelial cell dam-
age [8]. This gene is present in all strains and comprises
two variable parts [2,9], the s-region (signal) and the m-
region (middle) [3]. The production of vacuolating cyto-
toxin is related to the mosaic combination of s and m
allelic types. The mosaic combination of the vacA gene has
been associated with specific genotypes and different clin-
ical outcomes [3,4,10].
The gene designated, iceA (induced by contact with epi-
thelium), has two main allelic variants, iceA1 and iceA 2.
Although iceA1 has been associated with peptic ulcer dis-
ease [3], other studies have failed to confirm this correla-
tion, and some groups have suggested an inverse
relationship [5,11].
H. pylori infection can be cured by antibiotics, however the
ideal anti-H. pylori treatment has yet to be found [12,13].
Many factors have been implicated in treatment failure,
including ineffective penetration of antibiotics into the
gastric mucosa, antibiotic inactivation by low gastric pH,
lack of compliance, and emergence of acquired antibiotic
resistance by H. pylori [3,14]. Despite the success of the
current anti-Helicobacter therapies, it is suggested that
eradication rates among patients with gastritis are lower
than among patients with peptic ulcer disease, with the
causes of this phenomenon still being the subject of spec-
ulation [15].
In this study, we aimed to correlate primary resistance of
Brazilian H. pylori isolates to metronidazole, clarithromy-
cin, amoxicillin, tetracycline, and furazolidone with vacA,
iceA,  cagA and cagE status and clinical outcome.
Methods
Patients
Helicobacter pylori isolates were obtained from 155
patients (86 males and 69 females; age 43.6 ± 14.9 years)
living in southeastern Brazil. Eighty patients with peptic
ulcer disease (PUD), 54 with non-ulcer dyspepsia (NUD)
and 21 with gastroesophageal reflux disease (GERD) were
included. The study was approved by the Ethics Commit-
tee of the São Francisco University and performed in
accordance with the Declaration of Helsinki. Each patient
signed a written informed consent prior to entering the
study.
H. pylori culture and MIC determination
H. pylori isolates were obtained by inoculating the speci-
mens into selective media followed by incubation for 3–5
days at 37°C under microaerophilic conditions, as previ-
ously described [16]. The colonies were identified by
Gram staining and by oxidase, catalase and urease pro-
duction.  H. pylori strains were stored at -70°C in BHI
broth containing glycerol 30%. The MIC for amoxicillin,
furazolidone, metronidazole, tetracycline (Sigma Chemi-
cal Co., St Louis, MO) and clarithromycin (Abbot Labora-
tories, North Chicago, Ill) were determined by the agar
dilution method, using twofold increments (0.125 to 256
µg ml-1) on Mueller-Hinton agar (Merck, Darmstadt, Ger-
many) supplemented with 10% sheep blood, and incu-
bated at 37°C under microaerophilic conditions for 72 h.
All tests were performed in duplicate. Isolates were con-
sidered to be resistant when the MIC was greater than 8 µg
ml-1 for amoxicillin or metronidazole, and greater than 2
µg ml-1 for clarithromycin, furazolidone or tetracycline
[16].
Molecular Biology Methods
Genomic DNA was extracted with DNAzol™ reagent
(Gibco BRL, Cincinnati, OH, USA), and the integrity of
the DNA was assessed by electrophoresis in 0.8% agarose
gels stained with ethidium bromide.
Polymerase chain reactions (PCR) were performed in a
total volume of 50 µl containing 50 pmol of primer, 100
ng of genomic DNA, 1.0 mmol L-1 of each of four dNTPs
(Invitrogen™ Life Technologies, Alemeda, CA, USA) and
2.5 U of Taq DNA polymerase (Invitrogen™ Life Technol-
ogies). The reaction mixtures were cycled in an automated
GeneAmp® PCR System 9700 thermal cycler (PE Applied
Biosystems, Foster City, CA, USA) under the following
conditions: initial denaturation at 95°C for 5 min fol-
lowed by 35 cycles of denaturation at 95°C for 1 min,
annealing ranging from 45°C to 60°C for 1 min andBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/20
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72°C for 1 min. The final cycle included a 7 min extension
step to ensure full extension of the PCR products.
The presence of H. pylori was confirmed by PCR of the 16S
rRNA [17] and glmM [18] genes. The cagA gene was ana-
lyzed using the primers D008 and R008 [19]. The cagE
gene was analyzed using the primers described by Fallone
et al. [10]. For analysis of the vacA m region, primers VA3-
F and VA3-R were used, whereas primers VA4-F and VA4-
R were used to amplify the m1 and m2 subtypes, respec-
tively [5]. The vacA s region was analyzed using the prim-
ers, VA1-F and VA1-R [5]. For iceA  genotype analysis,
primers iceA1-F, iceA1-R, iceA2-F and iceA2-R were used.
The primers, iceA2-F and iceA2-R, yielded a fragment of
124, 229 or 334 bp depending on the existence of
repeated sequences of 105 nucleotides [3].
Statistical analysis
The association between H. pylori genotypes and clinical
disease, as well as among the virulence markers and anti-
biotic resistance was evaluated using either the χ2 test with
Yates continuity correction or Fisher's exact test. Only
cases containing single genotypes were included. Logistic
regression analysis was used to evaulate the relationship
between virulence markers and antibiotic resistance of H.
pylori and clinical outcome. A logistic regression model
was constructed using variables such as cagA, vacA and
iceA status, and antibiotic resistance. The association of
each variable with PUD or NUD or GERD (dependent var-
iables) was tested by univariated analysis. All variables
with p values of 0.25 or less were included in the full
model of logistic regression and variables with p values
<0.05 were remained in the model. The odds ratio (OR)
and the 95% confidence interval (95% CI) were used as
estimates of the risk.
Results and Discussion
Virulence factors
The presence of the genes vacA, cagA, cagE and iceA were
investigated in all 155 clinical isolates positive for 16S
rRNA and for glmM. Based on the vacA and iceA geno-
types, 138 (89%) specimens were colonized by a single H.
pylori strain. More than one strain was detected in 17 iso-
lates and none of these patients were included in either
the analysis of the relationship between clinical disease
with the virulence factors or with antibiotic resistance.
Since the prevalence of H. pylori infection, in our geo-
graphic region, reaches 80%, such prevalence of multiple
infection would be expected [20].
The vacA s and m genotype could be identified in all cases
studied. Most of the isolates had the s1 signal sequence
allele (62%). The prevalence of vacA s1 was significantly
higher in H. pylori isolates from PUD patients (χ2 = 14.3 p
= 0.0002). The vacA m1 allele was found in 41 (30%) and
the m2 allele in 97 (70%) of the samples. There was no
relationship between vacA m and clinical outcome. Con-
sidering the H. pylori isolates with only one single geno-
Table 1: The vacA, iceA, cagA and cagE status of H. pylori strains and clinical outcome
Clinical Outcome
Genotype PUD n (%) NUD n (%) GERD n (%) Total n (%)
vacA
s1 57 (78)* 25 (54) 4 (21) 86 (62)
s2 16 (22) 21 (46) 15 (79)** 52 (38)
m1 27 (37) 11 (24) 3 (16) 41 (30)
m2 46 (63) 35 (76) 16 (84) 97 (70)
s1m1 27 (37) 11 (24) 3 (16) 41 (30)
s1m2 30 (41)* 14 (30) 1 (5) 45 (32)
s2m2 16 (22) 21 (46) 15 (79)** 52 (38)
iceA
iceA1 12 (16) 6 (13) 3 (16) 21 (15)
iceA2 55 (75) 32 (70) 15 (79) 102 (74)
iceA - 6 (9) 8 (17) 1 (5) 15 (11)
cagA
cagA + 55 (75)* 25 (54) 9 (47) 89 (65)
cagA - 18 (25) 21 (46) 10 (53) 49 (35)
cagE
cagE + 60 (82) 39 (85) 17 (90) 116 (84)
cagE - 13 (13) 6 (15) 2 (10) 22 (16)
* vacA s1 (χ2 = 14.3; p = 0.0002) s1m2 (χ2 = 15.67; p = 0.0004) cagA (χ2 = 7.954; p = 0.0048). ** s2m2 (χ2 = 16.89; p = 0.0002)BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/20
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type (138), three mosaic combinations were found: s1m1
(30%), s1m2 (32%), and s2m2 (38%). Statistical analysis
showed a significant association between PUD and s1m2
(χ2 = 15.67; p  = 0.0004), and between GERD and the
s2m2 genotype (χ2 = 16.89; p = 0.0002, Table 1).
The iceA1 genotype was detected in 21 (15%) of the 138
isolates analyzed, while iceA2 was found in 102 cases
(74%). Fifteen isolates (11%) did not yield any PCR prod-
uct for iceA (Table 1). There was no relationship between
the size of the iceA2 amplicon and the patient's disease. In
contrast to results obtained by others, iceA2 was the most
frequent genotype detected in our population [21,22]. In
this study, the iceA type was not associated with the clini-
cal outcome, as previously described [11,21].
With regard to the cag PAI, the cagA gene was present in 89
(65%) of the 138 H. pylori isolates, whereas the cagE gene
was present in 116 (84%) isolates (Table 1). Both genes
were absent in 11% (15/138) of the isolates and, in these
cases, the cag PAI could also be absent. There was an asso-
ciation between PUD and the presence of the cagA (χ2 =
7.954; p = 0.0048). Our data are supported by previous
reports and suggest that individuals colonized with cagA-
positive H. pylori strains are at increased risk of developing
peptic ulceration [3,4]. Conversely, no association was
detected between cagE genotypes and clinical outcome.
The combination of the cagA and vacA status was also
investigated. An association was observed between the
genotype, cagA-positive vacA s1 and PUD (χ2 = 11.871; p
= 0.0006) and between GERD and the cagA-negative vacA
s2 genotype (p < 0.0001). Although our data showed a
trend towards an association between the cagA-positive,
vacA s1m2 genotype and PUD (χ2 = 13.849; p = 0.001),
logistic regression analysis suggested that this could be
explained by a higher prevalence of the cagA and vacA s1
alleles (OR = 5.42, 95% CI 2.6–11.3, p = 0.0006) This
finding agrees with those of others reports and suggests a
possible role for these factors in the pathogenesis of H.
pylori-related peptic ulceration [3,4]. Gastroesophageal
reflux disease (GERD) results from exposure of the
esophageal mucosa to acid [23]. There is no apparent
causal relationship between H. pylori colonization and the
presence of GERD or its complications, although GERD
patients are infected with less virulent H. pylori strains
[24]. Infection by H. pylori may protect against GERD,
thus these patients may have a lower frequency of vacA s1
genotype and a higher frequency of the vacA s2 and m2
genotypes [4,10,25]. Our data support this hypothesis
and logistic regression showed a negative association
between the more virulent strain, cagA-positive vacA s1
genotype, and GERD (OR = 0.26, 95% CI 0.08–0.8, p =
0.03). Although the protective effect of infection with
cagA-positive  H. pylori strains against GERD could be
explained by the lower gastric output due to the more
intense gastric lesions induced by these strains [26]. Fur-
ther studies are required to determine the putative protec-
tive role of the more virulent strains.
Antimicrobial Susceptibility
H. pylori resistance to antimicrobial is of particular con-
cern because it is a major determinant of eradication regi-
men failure. We tested the primary resistance to
amoxicillin, clarithromycin, furazolidone, metronidazole
and tetracycline in 138 H. pylori isolates.
Until recently, resistance to amoxicillin was considered to
be absent or very rare, however, amoxicillin-resistant H.
pylori strains have now been identified in USA, Italy and
Brazil [16,27,28]. In this study, the amoxicillin resistance
was found in 39% of isolates (54/138). The reason for
these high rates of amoxicillin resistance remains unclear,
however, since no pharmaco-epidemiological data
regarding amoxicillin use in Brazil exists, it may be specu-
lated that this drug is used in a disproportionate manner.
The increased consumption of macrolides is expected to
influence the prevalence of H. pylori resistance to clari-
thromycin. Resistance to clarithromycin was detected in
16% of strains (23/138). Our results agree with previous
reports from Brazil, being lower those from Peru [29] and
higher than rates in Europe [30]. Resistance to clarithro-
mycin has a serious clinical implication, since it impairs
the efficacy effect of anti-H. pylori treatment [31].
The occurrence of metronidazole-resistant strains may be
the consequence of increased consumption of this antibi-
otic in the community. In this study, the resistance to met-
ronidazol was observed in 54% (75/138) of strains.
Metronidazole has been widely prescribed for other infec-
tions such as parasitic or genital infections, and the use or
abuse of this inexpensive drug may contribute to the
increase in metronidazole resistance, with rates ranging
from 5% to 90% [32].
Tetracyclines are a family of broad-spectrum antibiotics
that have been widely used for the treatment of bacterial
infections since the 1950s. Until the end of the last cen-
tury, only a few cases of spontaneous tetracycline resist-
ance in H. pylori had been reported [33]. During the last 3
years, however, an increase in the incidence of tetracycline
resistance in H. pylori has been reported. In this study, we
found 9% (13/138) of tetracycline resistance in strains.
Similar data were published in previous reports [16,34].
Furazolidone has been used as an alternative to overcome
metronidazole resistance. In our study, resistance to fura-
zolidone was 13% (19/138), higher than rates detected by
others [22]. The reason for the high rate of furazolidoneBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/20
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resistance and factors leading to it are still unknown and
deserve further investigation.
Thirty one strains were resistant to two agents, 19 isolates
to three drugs, and 3 strains to four antimicrobials. H.
pylori resistance to these antimicrobials may be partially
explained by the high prevalence of this bacteria in our
population. Eradication failure has been associated with
several reasons, the most important being primary H.
pylori resistance.
Additionally, the primary H. pylori resistance was related
to the clinical outcome, as well as to virulence factors. We
were unable to detect an association between outcome
and bacterial resistance, as previously reported [35,36].
With regard to virulence factors, no association was found
when the MIC values for metronidazole, amoxicillin, clar-
ithromycin, tetracycline, and furazolidone were com-
pared with the different vacA,  iceA,  cagA and cagE
genotypes, as described by several authors [35,37]. Thus,
it seems that different virulence markers and antibiotic
resistance in H. pylori strains are not interrelated.
Conclusions
In conclusion, the analysis of virulence genes revealed a
specific association between H. pylori strains and clinical
outcome. Our data suggest an association between cagA-
positive, vacA s1 genotype, and PUD and also support the
hypothesis that virulent strains may protect against GERD
development. Furthermore, no significant correlation was
detected among pathogenicity and resistance or
susceptibility.
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